Comparing of Dare Bioscience Inc. (DARE) and Cleveland BioLabs Inc. (NASDAQ:CBLI)

Dare Bioscience Inc. (NASDAQ:DARE) and Cleveland BioLabs Inc. (NASDAQ:CBLI) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dare Bioscience Inc. N/A 0.00 22.95M -2.92 0.00
Cleveland BioLabs Inc. 1.77M 9.88 4.35M -0.39 0.00

Table 1 demonstrates Dare Bioscience Inc. and Cleveland BioLabs Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Dare Bioscience Inc. 0.00% -180.3% -166.4%
Cleveland BioLabs Inc. -245.76% -734.3% -56.6%

Volatility & Risk

Dare Bioscience Inc. has a 2.23 beta, while its volatility is 123.00%, thus making it more volatile than S&P 500. In other hand, Cleveland BioLabs Inc. has beta of -0.31 which is 131.00% less volatile than S&P 500.

Liquidity

The Current Ratio of Dare Bioscience Inc. is 8.5 while its Quick Ratio stands at 8.5. The Current Ratio of rival Cleveland BioLabs Inc. is 3.5 and its Quick Ratio is has 3.5. Dare Bioscience Inc. is better equipped to clear short and long-term obligations than Cleveland BioLabs Inc.

Insider and Institutional Ownership

Institutional investors held 21.3% of Dare Bioscience Inc. shares and 6% of Cleveland BioLabs Inc. shares. 1.2% are Dare Bioscience Inc.’s share held by insiders. Insiders Comparatively, held 58.15% of Cleveland BioLabs Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Dare Bioscience Inc. -4.87% -9.89% -18% -44.59% -66.67% -62.11%
Cleveland BioLabs Inc. -4.28% 1.7% -1.65% -33.95% -28.69% -55.36%

For the past year Dare Bioscience Inc. was more bearish than Cleveland BioLabs Inc.

Summary

On 6 of the 9 factors Cleveland BioLabs Inc. beats Dare Bioscience Inc.

Daré Bioscience, Inc. develops and commercializes product for women’s reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.